Abstract
Dual anti-platelet therapy remains a cornerstone in the management of patients suffering from acute coronary syndromes (ACS). The combination of aspirin and clopidogrel has been shown to result in significant reductions in cardiovascular end points including recurrent infarction and death in several randomised control trial of patients with ACS. However, many patients still experience ischaemic events on the combination of aspirin and clopidogrel. Aspirin is a relatively weak anti platelet agent. Clopidogrel is a pro drug that required activation by hepatic metabolism and hence its onset of action is delayed; there is genetic variation in the clinical response to the drug, the platelet inhibition is irreversible and no intravenous form is available. Consequently new anti-platelet agents have been developed to address the short falls of this combination therapy. This paper discusses existing anti-platelet regimes and focuses on novel antiplatelet agents that are currently under clinical evaluation.
Keywords: Acute coronary syndrome, aspirin, clopidogrel, prasugrel, ticagrelor, cangrelor, elinogrel, vorapaxar, atopaxar
Cardiovascular & Hematological Disorders-Drug Targets
Title: Anti-Platelet Therapy for Acute Coronary Syndrome: A Review of Currently Available Agents and What the Future Holds
Volume: 11 Issue: 2
Author(s): F. A. Syed, J. H.N. Bett and D. L. Walters
Affiliation:
Keywords: Acute coronary syndrome, aspirin, clopidogrel, prasugrel, ticagrelor, cangrelor, elinogrel, vorapaxar, atopaxar
Abstract: Dual anti-platelet therapy remains a cornerstone in the management of patients suffering from acute coronary syndromes (ACS). The combination of aspirin and clopidogrel has been shown to result in significant reductions in cardiovascular end points including recurrent infarction and death in several randomised control trial of patients with ACS. However, many patients still experience ischaemic events on the combination of aspirin and clopidogrel. Aspirin is a relatively weak anti platelet agent. Clopidogrel is a pro drug that required activation by hepatic metabolism and hence its onset of action is delayed; there is genetic variation in the clinical response to the drug, the platelet inhibition is irreversible and no intravenous form is available. Consequently new anti-platelet agents have been developed to address the short falls of this combination therapy. This paper discusses existing anti-platelet regimes and focuses on novel antiplatelet agents that are currently under clinical evaluation.
Export Options
About this article
Cite this article as:
A. Syed F., H.N. Bett J. and L. Walters D., Anti-Platelet Therapy for Acute Coronary Syndrome: A Review of Currently Available Agents and What the Future Holds, Cardiovascular & Hematological Disorders-Drug Targets 2011; 11 (2) . https://dx.doi.org/10.2174/187152911798347007
DOI https://dx.doi.org/10.2174/187152911798347007 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiomyopathy of Pregnancy
Current Women`s Health Reviews Gut Microbiota Modulation for Therapeutic Management of Various Diseases: A New Perspective Using Stem Cell Therapy
Current Molecular Pharmacology Thiazide Diuretics: 50 Years and Beyond
Current Hypertension Reviews Novelty in Treatment of Pulmonary Fibrosis: Pulmonary Hypertension Drugs and Others
Cardiovascular & Hematological Agents in Medicinal Chemistry The Impact of Type 2 Diabetes on Women’s Health and Well-being During Their Reproductive Years: A Mixed-methods Systematic Review
Current Diabetes Reviews Small-Molecules Targeting Kinases Involved in Pulmonary Hypertension: a Patent Review (2010-2015)
Current Medicinal Chemistry Microbubbles Contrast Agents: General Overview as Diagnostics and Therapeutic Agent
Current Drug Targets Endothelial Microparticles: Mediators or Markers of Endothelial Cell Dysfunction?
Current Hypertension Reviews Exercise Training-Associated Changes in Arterial Stiffness and Endothelium-Derived Vasoactive Factors
Current Hypertension Reviews Molecular Basis for the Neuroprotective Properties of FKBP-Binding Immunophilin Ligands
Current Medicinal Chemistry - Central Nervous System Agents A Novel Compound Heterozygous Gene Mutation of Dolichol Kinase Deficiency (DOLK-CDG)
Endocrine, Metabolic & Immune Disorders - Drug Targets GSK-3 Inhibitors: A New Class of Drugs for Alzheimer’s Disease Treatment
Current Drug Targets Plasma Phospholipids are Associated with Mild Cognitive Impairment in Type 2 Diabetic Patients
Current Alzheimer Research Intensive Insulin Therapy in Critical Care Settings
Current Clinical Pharmacology Preface
Current Pharmaceutical Design Use of Antiplatelet Therapy after Percutaneous Coronary Intervention with Bare-Metal Stents and Different Types of Drug-Eluting Stents
Current Clinical Pharmacology Structure-Based Discovery of PDEs Inhibitors
Current Topics in Medicinal Chemistry The Route of Neuro-Critical Care
Reviews on Recent Clinical Trials Drug Tissue Distribution: Study Methods and Therapeutic Implications
Current Pharmaceutical Design The Role of Autophagic Cell Death and Apoptosis in Irinotecan-treated p53 Null Colon Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry